Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT00139711
- Lead Sponsor
- Pfizer
- Brief Summary
A multicenter randomized phase II study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or metastatic non small cell lung cancer (NSCLC)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 138
Inclusion Criteria
- Histologically or cytologically proven NSCLC
- Recurrent or metastatic NCSLC
Exclusion Criteria
- Prior malignancies; except for cured non melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer adequately treated an with non evidence of disease for at least 5 years
- History or presence of brain or meningeal metastases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Evaluate the activity and tolerability of the association of irinotecan and docetaxel according to three different schedules as second line treatment for recurrent or metastatic NSCLC.
- Secondary Outcome Measures
Name Time Method Evaluate, in each arm, the time to progression, the duration of response and the survival
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇮🇹Varses, Italy